Company ProfilePremium

Patrys Limited

Company Profile Analysis

Ticker: PAB.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Patrys Limited - Company showcase

Year Founded & Workforce

2007

Patrys Limited logo

Patrys Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Patrys Limited Overview

Patrys Limited is an ASX-listed micro-cap biotechnology company that, over 2025–2026, transformed itself from a preclinical oncology antibody developer into a clinical-stage drug reformulation company. Its lead asset, RLS-2202, is a proprietary intravenous formulation of quetiapine — an established oral atypical antipsychotic — being developed to treat delirium in intensive care, aged care and palliative settings, where no drug is approved and clinicians rely on off-label agents. Acquired via the January 2026 purchase of Reliis Pty Ltd, the program entered a Phase 1a healthy-volunteer study in Adelaide in September 2026 and is intended to pursue the US FDA 505(b)(2) pathway, which allows reliance on existing quetiapine safety data. Patrys's legacy deoxymab antibody platform has been assigned to Yale University in exchange for a 50% share of future commercialisation revenue. The company holds A$3.36M cash, no debt, and remains dependent on equity markets to fund operations.


What the company does

Patrys is a drug development company with no commercial products, no revenue and an outsourced operating model. Its activities consist of (i) directing contract research organisations (CROs), contract development and manufacturing organisations (CDMOs) and clinical sites to generate data on its drug candidates, (ii) building and defending intellectual property, and (iii) seeking to create value via clinical milestones that can lead to licensing, partnering or acquisition.

The company's own description in its most recent disclosures (Phase 1a dosing announcement, 23 Sep 2026) characterises Patrys as a clinical-stage company developing an injectable therapy for delirium, alongside a differentiated deoxymab platform targeting immune-mediated inflammatory diseases. The FY2024 Annual Report, by contrast, described the company as leveraging its proprietary deoxymab antibody platform to develop therapies for cancer and other diseases — illustrating the scale of the 2025–26 pivot.

Business model and revenue model

Revenue model elementStatusCommentary
Product sales—No approved products
Services——
Subscription——
Licensing / royaltiesNone currently; potential futureThe 13 Jul 2026 Yale agreement entitles Patrys to 50% of Yale's future deoxymab commercialisation revenue (cash, equity, licensing income, royalties, milestones). Historical licensing income was A$27.5k in FY2022 (Hefei Co-Source / PAT-SC1) and nil thereafter.
Government grants (R&D Tax Incentive)Historically material; nil recognised FY2026A$3.30M (FY2022), A$2.78M (FY2023), A$1.29M (FY2024), A$0.81M (FY2025), nil (FY2026). For FY2026 management judged there was insufficient evidence to recognise an R&D incentive receivable (AASB 120 judgement).
InterestMinorA$9.0k in FY2026

Intended monetisation path (company presentation, Jul 2026): develop RLS-2202 through Phase 1a (healthy volunteers) and Phase 1b (ICU delirium patients), file an FDA pre-IND (targeted Q1 2027) and IND (targeted Q1 2028), and identify a "potential partnering / licensing point" around the Phase 1b/pivotal transition. The company cites a total development cost of roughly US$20–30M over 3–5 years for the reformulation, versus a commonly cited ~US$1.2B and 10–15 years for a new molecular entity (company presentation; these are management estimates, not audited figures).

Value chain position

Patrys sits at the asset-ownership / development-management layer of the pharmaceutical value chain. It does not discover new molecules (quetiapine is a known drug), does not manufacture (BioCina, Adelaide, performed engineering and GMP batches), and does not run clinical sites (CMAX, Adelaide) or trial management (Alithia Life Sciences). Its value-add is the proprietary formulation IP, the regulatory strategy (505(b)(2)), and capital allocation.

Customer types and end-markets (prospective)

Prospective customerEnd-marketNotes
Hospitals / ICUsCritical care deliriumCompany cites up to 80% of ICU patients experiencing delirium (Richardson et al. cited in presentation)
Aged-care facilitiesGeriatric delirium / agitationStated target setting
Palliative careTerminal agitation / deliriumStated target setting
Pharma licenseesPartneringMost likely near-term "customer" for the asset
Yale University / Nucleicon (Yale venture)Deoxymab platformPatrys is a passive 50% revenue participant

Independent characterisation

Patrys is best described as a single-asset, early-clinical, specialty-pharma reformulation shell with a residual antibody royalty interest. The legacy company (antibody discovery, 2007–2025) consumed approximately A$88.9M of accumulated losses (balance at 30 June 2026) without producing a clinical-grade drug for its deoxymab program; the board and management were replaced in 2025–26 by a Perth-based group with capital-markets and micro-cap biotech backgrounds, which bought in Reliis via an all-scrip transaction. The investment case now rests almost entirely on RLS-2202 producing a clean pharmacokinetic/safety profile and on the company's ability to fund a Phase 1b ICU study and FDA interactions.

Strategy

Stated strategy themes (paraphrased from 2026 disclosures)

  1. Reformulate a proven drug for a faster, lower-risk path — take quetiapine, with decades of human safety data, into an IV form for acute care; use 505(b)(2) to rely on existing data.

  2. Capital-efficient execution — conduct manufacturing and CMC work alongside Phase 1a to move quickly into Phase 1b; company estimates US$20–30M total development cost.

  3. De-risk across value drivers — management argues the asset carries lower market, IP, manufacturing, regulatory and adoption risk than a typical biotech program (management's own risk matrix; not independently validated).

  4. Monetise the legacy platform without funding it — the Yale assignment preserves 50% economic exposure to deoxymabs while removing most future R&D cost.

  5. Partnering / licensing — the company flags a potential partnering point around Phase 1b / pivotal transition.

Strategic initiatives in the last 24 months

InitiativeDateDescriptionStatus
Corporate restructure & board renewalJun–Nov 2025Board replaced; CEO role made redundant; office moved to Perth; costs cutComplete
RecapitalisationJun 2025 – Apr 2026A$308k placement; ~A$1.77M entitlement offer; 15:1 consolidation; A$3.15M placement + A$160k director placementComplete
Reliis acquisitionNov 2025 – Jan 2026All-scrip purchase of injectable quetiapine programComplete
RLS-2202 Phase 1aMay – Q4 2026CMAX site, Alithia CRO, BioCina manufacturing, HREC approval, dosingOngoing
US regulatory engagementFrom Mar-26 quarterPreparing FDA pre-IND (target Q1 2027)Ongoing
Deoxymab assignment to Yale13 Jul 202650% revenue share; Patrys contributes A$150,000 toward ongoing deoxymab costs (per StockWire X summary)Binding agreement; completion mechanics not detailed
Cost rationalisationFY2026Sigma-Aldrich CHOZN licence terminated 30 Jun 2026; staff reducedComplete

No ESG or sustainability commitments have been announced. No formal cost-programme targets were published.

Management guidance / targets (company presentation, Jul 2026, updated by Sep 2026 announcements)

MilestoneTarget
Ethics approval Phase 1aQ3 2026 — achieved 28 Aug 2026
Phase 1a initiationQ3 2026 — achieved 23 Sep 2026
Cohort 1 completeAchieved 29 Sep 2026
Safety Review CommitteeOctober 2026
GMP clinical batch release / Cohort 2 dosingQ4 2026
Phase 1a completion (final participant dosed)Q4 CY2026
FDA pre-IND submissionQ1 2027
6-month drug product stability for CMCQ1 2027
Phase 1b ethics approvalQ2 2027
Phase 1b first patient dosedQ3 2027
Phase 1b completionQ4 2027
IND submissionQ1 2028

No revenue, earnings or cash-burn guidance has been issued.

Products & Services

Patrys has no marketed products. The pipeline is catalogued below, organised by program family.

Reformulation platform (Reliis)

RLS-2202 — intravenous (injectable) quetiapine (lead asset)

Description: A proprietary injectable formulation of quetiapine, an atypical antipsychotic long used orally for schizophrenia and bipolar disorder. Developed for rapid, predictable treatment of delirium in acute care.

Rationale (company presentation, Jul 2026): Oral quetiapine is the most commonly prescribed antipsychotic in delirium (company cites 47% share of antipsychotic use, ahead of haloperidol at 40%, per Alghadeer et al. 2024), but is slow-onset (1–2 hours) and hard to administer to agitated or sedated patients. The company argues IV dosing can reduce exposure to the active metabolite norquetiapine, which it links to many side effects.

Development stage: Phase 1a (first participants dosed Sep 2026). Cohort 1 (n=4) received both a reference oral quetiapine dose and RLS-2202; Cohort 2 GMP material manufactured; final dosing targeted Q4 CY2026.

Regulatory route: FDA 505(b)(2). Australian trial run under TGA Clinical Trial Notification (CTN) scheme.

IP: Australian provisional patent 2022901032; PCT/AU2023/050316; national phase entered Q4 2024 in the US, EU/UK and Australia, covering formulation composition, method of use in delirium, and delivery formulation; company states protection to ~2042, wholly owned with no trailing obligations. A further provisional application covering new IP was filed in 2026.

Manufacturing: BioCina (Adelaide) — engineering batch commenced March 2026 quarter; GMP manufacturing and filling for Cohort 2 completed by Sep 2026.

Target customer: ICU, aged-care and palliative-care prescribers; ultimately pharma licensee.

Pricing model: Not disclosed.

Note on naming: At acquisition (Nov 2025 – Jan 2026) the program was named RLS-2201; from the March 2026 quarter onward, disclosures refer to RLS-2202. The sources reviewed do not explicitly explain the change; it coincides with a new 2026 provisional patent filing and an IV-focused formulation. Investors should confirm the relationship in the audited FY2026 Annual Report.

Deoxymab antibody platform (legacy; being assigned to Yale)

CandidateFormatKey properties (company disclosures)Status at Oct 2026
PAT-DX1Dimer of humanised single-chain binding fragment of 3E10Cell- and nucleus-penetrating via ENT2 transporter; crosses blood-brain barrier; inhibits DNA damage repair; preclinical activity in glioma (with radiation), TNBC, metastasis models; inhibits NETosisPhase 1 abandoned after GMP batch failed specification testing (2 Oct 2024); out-licensing sought; to be assigned to Yale
PAT-DX3Full-length humanised IgG of 3E10Same binding domain; better yield/stability; crossed BBB in healthy animals (Oct 2022; 3–4× uptake vs control); synthetic lethality in BRCA2-deficient models (Mar 2023); reduced kidney injury in ANCA vasculitis model (Apr 2024)Preclinical; MCB and GLP-grade process established; to be assigned to Yale
PAT-DX1-NPPAT-DX1 conjugated to nanoparticles carrying payloadsTargeted delivery to tumoursPreclinical (FY2023 pipeline chart)
Deoxymab conjugates (ADC / AOC concepts)PAT-DX3 conjugated to nucleic acids / small moleculesDelivery into nucleus avoiding endosomal degradationExploratory partner-funded experiments (FY2023)

All deoxymabs derive from 3E10, an autoantibody identified in a mouse model of systemic lupus erythematosus, licensed from Yale.

Deoxymab IP estate (FY2024 Annual Report): 12 active patent families, 18 granted patents and 32 pending applications, plus one international PCT application and one US provisional; protection potentially to at least 2044.

Legacy IgM antibodies (exited)

PAT-SM6 (natural human IgM; melanoma and multiple myeloma trials circa 2010–2015), PAT-LM1 and PAT-SC1 (gastric cancer; China rights with Hefei Co-Source terminated Sep 2022). No longer in development.

Financial Narrative

Sources: FY2023 Annual Report (FY2022 comparatives), FY2024 Annual Report, FY2026 Appendix 4E (FY2025 comparatives). All AUD thousands unless stated.

Income statement

Notes:

  • Share-based payments were embedded within R&D/admin expense lines in FY2022–FY2024 (disclosed in notes) and shown separately in FY2026; the "Total operating expenses" row sums the face-of-P&L lines only and does not double count.

  • EBITDA defined as pre-tax loss + D&A − interest income (no interest expense; no debt). FY2025 EBITDA includes the A$303.8k impairment (non-cash); excluding it, FY2025 EBITDA would be −A$2,681.5k. FY2022 D&A not disclosed in the documents reviewed.

  • FY2025 EPS (−2.20c) and FY2026 EPS are as reported post-consolidation; FY2022–FY2024 adjusted figures are reported values ×15.

  • Gross, operating, EBITDA and net margins and revenue CAGR are not meaningful (nil revenue).

Half-year split FY2026 (Appendix 4D / 4E): H1 FY2026 loss A$3,021,202 versus full-year loss A$3,414,590, implying an H2 loss of only ~A$393k. Given reported quarterly operating cash outflows of A$748k (Mar-26 quarter) and ~A$789k (Jun-26 quarter), the low implied H2 accounting loss likely reflects year-end reclassifications (e.g., acquisition accounting or capital-raising costs moving to equity) — a point to verify in the audited accounts.

Commentary. The P&L tells a story of a company that wound down a costly manufacturing-heavy antibody program. R&D spend fell 79% from A$8.09M (FY2022) to A$1.71M (FY2026). The key inflection was FY2024, when the PAT-DX1 GMP campaign concluded and spending halved; FY2025 then absorbed the October 2024 specification failure and a full write-off of the Nucleus IP. FY2026 R&D was nearly flat year-on-year in absolute terms but its composition changed completely — from deoxymab residual activity to RLS-2202 manufacturing (BioCina), regulatory and trial set-up. The most important adverse change in FY2026 is the loss of R&D Tax Incentive income (nil recognised vs A$807k in FY2025): the company did not lodge claims during the restructuring period and management judged that recognition criteria were not met at 30 June 2026. Any future recognition would be upside to reported income and cash.

Balance sheet

Commentary. The balance sheet bottomed at 30 June 2025 with equity of just A$733k and cash of A$742k — a near-distress position. FY2026 rebuilt it via ~A$5.0M of cash equity and ~A$7.85M of scrip issued for Reliis. The A$7.57M of goodwill and IPR&D now represents 68% of total assets; this intangible is valued using an income approach (Relief from Excess Earnings Method) with probability-of-success assumptions, and the company itself warns that changes in assumptions could cause a material change in value. Effective shareholder dilution since 30 June 2024 is ~4.9× on a consolidation-adjusted basis (137.1M → 666.5M shares). Trade payables jumped from A$136k to A$679k, reflecting trial and manufacturing activity.

Cash flow

Quarterly cash (Appendix 4C):

(Q4 outflow per Kalkine/Webull summaries of the June-quarter 4C describing ~A$789k of expenditure; treat as approximate.) The September-2026 quarter Appendix 4C (due by end-October 2026) was not located during this research.

Commentary. Free cash burn was reduced from ~A$8.7M (FY2022) to ~A$1.8M (FY2024–FY2025) through program wind-down, then rose to A$2.2M in FY2026 as RLS-2202 moved toward clinic and R&D refunds disappeared. At a run-rate of ~A$0.75–0.8M per quarter before trial cost escalation, the A$3.36M June 2026 cash balance implied roughly four quarters of runway — consistent with the directors' statement that further capital will be needed within twelve months. Phase 1b ICU work (targeted 2027) would require materially more capital.

Ratios

ROIC, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle are not meaningful (no revenue, no debt, no invested capital generating returns). The falling ROA denominator in FY2026 reflects the acquired intangible, not improved economics.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Results by Segment

MetricFY2022FY2023FY2024FY2025FY2026

Segment revenue — Biopharma R&D (AUD K)

00000

Segment other income — Biopharma R&D (AUD K)

3,333.62,851.91,394.2828.59.0

Segment pre-tax loss — Biopharma R&D (AUD K)

-6,780.4-7,061.6-3,539.2-3,013.3-3,414.6

Contribution to group revenue (%)

00000

Group Entities

EntityRoleProgram

Patrys Limited

Listed parent; board, capital raising

Group

Reliis Pty Ltd

Wholly owned since 28 Jan 2026

RLS-2202 (injectable/IV quetiapine), carried as A$6.75M IPR&D intangible plus A$0.82M goodwill

Nucleus Therapeutics Pty Ltd

Wholly owned since 2016

Deoxymab IP (PAT-DX1, PAT-DX3), carrying value nil; to be assigned to Yale under 13 Jul 2026 agreement

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue (AUD K)

00000

R&D Tax Incentive income (AUD K)

3,298.02,775.01,285.0807.30

Interest income (AUD K)

8.176.9109.121.39.0

Licensing income (AUD K)

27.50000

Total other income (AUD K)

3,333.62,851.91,394.2828.59.0

R&D expense (AUD K)

8,085.27,524.83,071.81,754.21,706.4

Administration & management expense (AUD K)

2,028.72,388.71,861.51,783.91,567.2

Impairment of intangibles (AUD K)

000303.80

Share-based payments expense (AUD K)

572.1465.5163.30150.0

Total operating expenses (AUD K)

10,113.99,913.54,933.33,841.83,423.6

Gross profit (AUD K)

00000

Operating result before other income (AUD K)

-10,113.9-9,913.5-4,933.3-3,841.8-3,423.6

Depreciation & amortisation (AUD K)

—47.047.049.30.3

EBITDA (AUD K)

—-7,091.5-3,601.3-2,985.3-3,423.2

Pre-tax loss (AUD K)

-6,780.4-7,061.6-3,539.2-3,013.3-3,414.6

Income tax (AUD K)

00000

Net loss (AUD K)

-6,780.4-7,061.6-3,539.2-3,013.3-3,414.6

Basic EPS as reported (AUD cents)

-0.3458-0.3436-0.1722-2.20-0.83

Basic EPS consolidation-adjusted (AUD cents)

-5.19-5.15-2.58-2.20-0.83

Diluted EPS (AUD cents, as reported)

-0.3458-0.3436-0.1722-2.20-0.83

Dividends per share (AUD cents)

00000

Balance Sheet and Share Count (millions)

MetricFY2022FY2023FY2024FY2025FY2026

Cash & cash equivalents (AUD K)

7,817.83,045.52,240.7742.43,360.1

Term deposits >3 months (AUD K)

2,004.01,000.0000

Trade & other receivables (AUD K)

3,411.32,842.11,341.8825.3100.5

Total current assets (AUD K)

13,527.67,129.13,808.51,739.13,523.2

Goodwill (AUD K)

0000820.0

Other intangibles (AUD K)

438.8393.8348.806,750.0

Total assets (AUD K)

13,970.07,524.54,161.61,739.111,096.7

Total liabilities (AUD K)

542.8686.9691.41,006.2918.6

Short-term debt (AUD K)

00000

Long-term debt (AUD K)

00000

Net debt incl. term deposits (AUD K)

-9,821.8-4,045.5-2,240.7-742.4-3,360.1

Total equity (AUD K)

13,427.26,837.63,470.2732.910,178.2

Issued capital (AUD K)

85,723.785,730.185,734.486,010.494,214.6

Accumulated losses (AUD K)

-74,296.3-81,119.4-83,874.2-86,203.0-88,875.5

Working capital as reported ex-prepayments (AUD K)

12,690.36,200.72,893.7561.52,604.7

Shares on issue at year end (millions, as reported)

2,055.32,055.62,055.82,364.1666.5

Shares on issue at year end (millions, consolidation-adjusted)

137.0137.0137.1157.6666.5

NTA per share (AUD cents, as reported)

0.630.310.150.050.05

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (AUD K)

-8,679.2-5,778.8-1,815.9-1,774.2-2,170.1

of which R&D Tax Incentive receipts (AUD K)

1,188.63,347.32,731.61,285.0807.2

Payments to suppliers & employees (AUD K)

-9,906.3-9,202.9-4,650.6-3,081.0-2,986.3

Capex (AUD K)

-2.30-3.20-3.9

Free cash flow (AUD K)

-8,681.5-5,778.8-1,819.2-1,774.2-2,174.0

Gross equity proceeds (AUD K)

7,901.66.44.3308.45,034.6

Net financing cash flow (AUD K)

7,556.46.44.3276.04,791.7

Dividends paid (AUD K)

00000

Buybacks (AUD K)

00000

Net change in cash (AUD K)

870.9-4,772.4-804.9-1,498.22,617.7

Key Financials

MetricQ2 FY2026 (Dec-25)Q3 FY2026 (Mar-26)Q4 FY2026 (Jun-26)

Net operating cash outflow (AUD K)

674748789

Closing cash (AUD K)

1,9041,1963,360

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

ROE on average equity (%)

-53.2-69.7-68.7-143.4-62.6

ROA on year-end assets (%)

-48.5-93.8-85.0-173.3-30.8

Current ratio (x)

24.910.45.51.73.8

Debt to equity (x)

00000

R&D as % of total operating expenses (%)

79.975.962.345.749.8

R&D net of R&D Tax Incentive income (AUD K)

4,787.24,749.81,786.8946.91,706.4

Geographic Revenue

MetricFY2024FY2025FY2026

Revenue — Australia (AUD K)

000

Revenue — Americas (AUD K)

000

Revenue — EMEA (AUD K)

000

Revenue — Rest of APAC (AUD K)

000

Share Price

MetricFY2021FY2022FY2023FY2024

Share price at FY end as reported (AUD)

0.0560.0200.0100.007

Share price at FY end consolidation-adjusted (AUD)

0.840.300.150.105

Valuation Multiples

MultiplePatrysComment

P/E

n/m

Loss-making

EV/EBITDA

n/m

Negative EBITDA

EV/Sales

n/m

No revenue

P/B

~2.5x

A$25.64M market cap / A$10.18M equity (30 Jun 2026)

P/tangible book

~9.8x

Tangible equity ~A$2.61M after excluding A$7.57M intangibles

EV

A$22.3M

Company figure, 24 Jul 2026

Capital Instruments

InstrumentNumberTermsSource

Underwriting fee options

68,666,660

A$0.024, exp. 30 Nov 2029

FY2026 4E

Broker fee options

9,999,996

A$0.024, exp. 30 Nov 2029

FY2026 4E

Sub-underwriting options (Christie, Uvarov)

7,499,999

A$0.024, exp. 30 Nov 2029

FY2026 4E

Leedman incentive options

5,000,000

A$0.040, exp. 10 Feb 2029

FY2026 4E

April 2026 placement attaching options

~33M (1 for 4)

A$0.048

ASX 20 Apr 2026 (subject to approval; obtained 8 Jun 2026)

Reliis performance rights

70,000,000

Milestone-based

FY2026 4E

Analyst Conclusions

Management guidance

Clinical milestone guidance only: Phase 1a completion Q4 CY2026, FDA pre-IND Q1 2027, Phase 1b first patient Q3 2027, IND Q1 2028. No financial guidance. Directors expect to require additional capital within twelve months of 31 Aug 2026.

Consensus

None (no broker coverage).

Bull case

  1. Execution credibility: the new team took an acquired asset from completion (Jan 2026) to first-in-human dosing (Sep 2026) in under eight months, on the timetable promised in May 2026.

  2. Asymmetric market structure: with no approved delirium drug and quetiapine already the most-used antipsychotic in delirium, a clean PK/safety bridge could make RLS-2202 a credible licensing target at a modest development cost (company estimate US$20–30M).

  3. Free optionality: the 50% deoxymab revenue interest and residual R&D Tax Incentive claims provide upside not reflected in a ~A$22M EV.

Bear case

  1. Financing overhang: A$3.36M cash, quarterly burn ~A$0.8M before Phase 1b costs, and a going-concern uncertainty point to further dilutive raises — likely before value-inflecting Phase 1b data.

  2. Clinical/regulatory unknowns: IV antipsychotic safety, FDA acceptance of bridging, and the historic difficulty of proving efficacy in delirium could each delay or derail the program.

  3. Track record and governance: accumulated losses of A$88.9M, the PAT-DX1 manufacturing failures, a board with limited independence, and an intangible-heavy balance sheet (68% of assets) warrant a significant risk discount.

Catalysts and monitorables (next 12 months)

TimingCatalyst
Oct 2026Safety Review Committee decision on Cohort 1; Cohort 2 dosing commencement
Late Oct 2026Sep-26 quarter Appendix 4C (cash runway)
Oct–Nov 2026Audited FY2026 Annual Report (confirm going-concern wording, remuneration, top-20 holders); AGM
Q4 CY2026Final Phase 1a dosing; top-line PK/safety readout timing
Q1 2027FDA pre-IND submission and feedback; 6-month CMC stability data
H1 2027Capital raise (high probability) and R&D Tax Incentive claim/receipt
Q2–Q3 2027Phase 1b ethics approval and first ICU patient dosed
OngoingYale/Nucleicon progress on deoxymabs; any partnering discussions

Analyst verdict

Patrys Limited in October 2026 is a fundamentally different company from the one that listed in 2007. Nearly two decades and roughly A$89M of accumulated losses were spent on antibody platforms — first natural human IgMs, then Yale's cell-penetrating deoxymabs — without a clinical-grade product reaching patients; the October 2024 PAT-DX1 specification failure effectively ended that chapter and pushed the company to the brink, with equity of under A$1M by June 2025. The subsequent recapitalisation, board replacement and all-scrip acquisition of Reliis have produced a credible, focused story: an IV formulation of quetiapine for delirium, now in human testing, pursued via a regulatory route that leans on decades of existing data.

The operational evidence since January 2026 is encouraging — every guided milestone through Cohort 1 completion has been met on time — and the Yale transaction sensibly converts a cash drain into a free option. The scientific premise is reasonable: clinicians already favour quetiapine in delirium, and the main obstacle is the route of administration.

However, the investment case remains binary and capital-constrained. Phase 1a will only establish PK and tolerability; proof of clinical benefit must await Phase 1b in ICU patients (targeted 2027) and ultimately a global pivotal study the company cannot fund alone. With A$3.36M cash at June 2026, an explicit going-concern uncertainty, roughly 28% potential dilution from outstanding options and rights, and a balance sheet dominated by an income-approach IPR&D valuation, near-term equity raises appear unavoidable. Governance — a small, closely held board including vendor directors — adds further risk.

On balance, Patrys suits only speculative, high-risk capital: the risk/reward hinges on a clean Phase 1a readout and constructive FDA pre-IND feedback, which together would materially improve its ability to raise funds or attract a partner. Absent those, dilution is likely to erode per-share value.


All figures from company filings unless otherwise noted; FY2026 figures unaudited.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackgroundCompensation

Dr Samantha South

Chief Executive Officer

Since 16 Feb 2026

Founding Director of Argenica Therapeutics (ASX: AGN) and former VP Non-Clinical Development there (2023–24 per MarketScreener); former NED of Reliis Pty Ltd before its acquisition; Chair of Life Sciences WA board; CNS research background; prior preclinical/regulatory roles at CROs; ~15 years in medtech/biotech technology transfer; PhD, MBA, GAICD

Not publicly disclosed in sources reviewed (FY2026 remuneration report not located)

Johnathon Busing and Kieran Witt

Joint Company Secretaries

Since 10 Nov 2025

Not detailed in sources reviewed

—

“—” = not publicly disclosed.

Board of Directors

NameRoleAppointedBackgroundIndependence (analyst view)

Peter Christie

Non-Executive Chair

Director from 17 Jun 2025; Chair during 2025

25+ years ASX governance; Chair of Moho Resources (ASX: MOH); NED Mount Ridley Mines (ASX: MRD); former Chair 3D Medical; former director ResApp Health; Curtin University graduate (1983); former portfolio manager, Allstate Investment Management

Participated in 2025–26 raisings and sub-underwriting; likely independent under ASX definitions but a material option holder

Dr Anton Uvarov

Non-Executive Director

Elected AGM 9 Oct 2025

Former Citigroup healthcare equities analyst; co-founder/director of multiple ASX companies including BlinkLab, Elsight, Dimerix, Actinogen, Neuroscientific Biopharmaceuticals

Significant shareholder and sub-underwriter (6.67M sub-underwriting options); not independent in substance

Brian Leedman

Non-Executive Director

10 Nov 2025

Co-founder of ResApp Health (acquired by Pfizer); chair/director roles at BlinkLab, Alcidion, OncoSil, Neuroscientific Biopharmaceuticals

Received 5M incentive options (A$0.04, exp. 10 Feb 2029); likely independent

Leanne Kite

Non-Executive Director

28 Jan 2026

Co-founder of Reliis; 20+ years capital markets, finance and IR; IR for Liontown Resources; 13 years in senior finance roles at Woodside Energy (per StockWire X)

Reliis vendor; holds 36.6M shares — not independent

Dino Cercarelli

Non-Executive Director

28 Jan 2026

Co-founder of Reliis; COO of Australian Clinical Trials Alliance; clinical trial operations leader

Reliis vendor; holds 21.4M shares — not independent

Board of Directors (Annual)

NameRoleTotal FY2023 (AUD)Total FY2024 (AUD)Notes

Dr James Campbell

MD & CEO (13 Apr 2015 – 30 Jun 2025)

735,443487,074

FY2023 included A$104,085 bonus and A$221,558 share-based payments; FY2024 salary A$372,649, super A$27,500, SBP A$43,397. Package A$416,555 from 1 Jul 2024. Role made redundant 1 Jul 2025; received 10.7M shares at A$0.015 (A$160,527) in Oct 2025 in lieu of accrued salary and non-statutory termination payments.

Dr Charmaine Gittleson

Chair (16 Nov 2022 – 2025)

83,768106,943

Fee A$95,430 p.a.

Dr Pamela Klein

NED (Oct 2019 – 2025)

90,52491,425

Paid USD 60,000

Suzy Jones

NED (Dec 2011 – Sep 2023)

97,96418,758—

Michael Stork

NED / Deputy Chair (Feb 2007 – 2025)

1,2470

No cash fees; held 98.8M shares (pre-consolidation) via Stork Holdings

Total KMP

—1,039,621704,200—

Board & Management Changes

DateChange

17 Jun 2025

Peter Christie appointed director

1 Jul 2025

CEO role made redundant; Campbell becomes NED

9 Oct 2025

AGM elects Christie and Uvarov; re-elects Campbell

10 Nov 2025

Campbell resigns; Leedman appointed; Busing and Witt appointed joint company secretaries

28 Jan 2026

Kite and Cercarelli appointed on Reliis completion

16 Feb 2026

Dr Samantha South commences as CEO

Directors' Shareholdings

DirectorSharesOptions / rightsSource

Leanne Kite

36,629,087—

MarketIndex (28 Jan 2026)

Dino Cercarelli

21,433,740—

MarketIndex (28 Jan 2026)

Anton Uvarov

—

6,666,666 sub-underwriting options at A$0.024, exp. 30 Nov 2029

InvestSMART director-interest log; FY2026 4E

Peter Christie

—

833,333 sub-underwriting options at A$0.024

Same

Brian Leedman

2,000,000

5,000,000 options at A$0.04

MarketIndex (10 Feb 2026)

Competitive Landscape

Key Competitors

Competitor / productOwnerRelevancePositioning vs RLS-2202

IV/IM haloperidol (generic)

Multiple generic makers

Most-used typical antipsychotic in delirium (company cites 40% share)

Cheap, entrenched; QTc and extrapyramidal risk

Dexmedetomidine IV (Precedex and generics)

Pfizer/Hospira and generics

ICU sedation used off-label for agitated delirium

Strong ICU incumbency; sedation-focused

Sublingual dexmedetomidine (Igalmi)

BioXcel Therapeutics

Approved for agitation in schizophrenia/bipolar, not delirium

Shows regulatory precedent for reformulated acute-agitation products

Oral quetiapine (generic)

Multiple

Most-prescribed antipsychotic in delirium (company cites 47%)

Same molecule; slow onset; RLS-2202 aims to supersede in acute settings

Olanzapine (oral/IM/sublingual)

Lilly and generics

Off-label use (company cites 9%)

Alternative atypical

Risperidone (generic)

Multiple

Off-label use (company cites 4%)

—

Benzodiazepines / sedatives

Multiple

Used despite worsening some delirium

Generally not recommended

IL-6 inhibitors, minocycline

Various

Listed by Patrys as being assessed in delirium

Early-stage alternative mechanisms

Key Competitors by Peer

PeerTickerRelevance

Argenica Therapeutics

ASX: AGN

CNS neuroprotection; CEO's former company

Actinogen Medical

ASX: ACW

CNS; Uvarov board link

Neuroscientific Biopharmaceuticals

ASX: NSB

CNS; Uvarov and Leedman links

Dimerix

ASX: DXB

Inflammation/renal; Uvarov link

Percheron Therapeutics

ASX: PER

Former Chair Gittleson's company

Prescient Therapeutics

ASX: PTX

Former CEO Campbell's board seat

BlinkLab

ASX: BB1

Leedman/Uvarov-associated micro-cap

BioXcel Therapeutics

NASDAQ: BTAI

Acute agitation reformulation precedent

Competitor Detail

MetricPatrys (FY2026)

Revenue

A$0

Revenue growth

n/m

Net loss

A$3.41M

R&D intensity (% of opex)

49.8%

Cash

A$3.36M

Market cap

~A$25.6M (Jul 2026)

Company Snapshot

2007

Founded

Perth region, Australia

Headquarters

SWOT Analysis

Strengths

  • Clinical-stage status achieved on schedule: HREC approval 28 Aug 2026; first dosing 23 Sep 2026; Cohort 1 completed 29 Sep 2026 — matching the Q3 2026 target set in May 2026.
  • Known active ingredient: quetiapine's decades of oral use underpin the 505(b)(2) strategy and reduce discovery risk (company presentation, Jul 2026).
  • Owned IP without trailing obligations: PCT/AU2023/050316 national phase in US, EU/UK, AU; ~2042 expiry (company presentation).
  • No debt: nil borrowings in every year FY2022–FY2026 (Annual Reports / 4E).
  • Retained deoxymab upside at near-zero cost: 50% of future Yale commercialisation revenue (13 Jul 2026).
  • Manufacturing in place: GMP manufacturing and fill completed for Cohort 2 at BioCina (23 Sep 2026 announcement).

Weaknesses

  • Going-concern uncertainty: directors state further capital is needed within 12 months; auditor expected to include a material-uncertainty paragraph (FY2026 4E).
  • Thin cash: A$3.36M at 30 Jun 2026 against ~A$0.75–0.8M quarterly burn (4C reports).
  • Single meaningful asset: RLS-2202 is effectively the entire valuation; deoxymab now passive.
  • Track record of manufacturing failure: PAT-DX1 failed GMP specification testing after multiple runs (2 Oct 2024).
  • Heavy dilution: consolidation-adjusted share count rose from 137.1M (FY2024) to 666.5M (FY2026).
  • Limited independent board and lean team: two directors are Reliis vendors; no disclosed CFO/CMO.

Opportunities

  • No approved delirium drug: first-mover potential in an acute-care niche (company cites >US$2B SAM).
  • Reformulation deal precedents: company cites Mallinckrodt's US$1.4B acquisition linked to IV paracetamol (Ofirmev) as an oral-to-IV precedent.
  • R&D Tax Incentive recovery: no incentive recognised for FY2026; future claims (refundable offset of up to 48.5% for eligible spend, per FY2024 AR) could materially extend runway.
  • Partnering at Phase 1b: company flags a licensing point before the pivotal study.
  • Deoxymab revenue via Nucleicon/Yale: potential milestone or equity receipts without capital outlay.
  • Option exercise funding: April 2026 placement options at A$0.048 and 68.7M underwriter options at A$0.024 (exp. 2029) could bring in cash if the share price rises.

Threats

  • Phase 1a safety/PK disappointment: IV antipsychotic administration could reveal QTc, hypotension or sedation issues; Safety Review Committee pending (Oct 2026).
  • FDA disagreement on 505(b)(2) bridging: pre-IND feedback (Q1 2027) could require more studies.
  • Difficult delirium efficacy endpoints: class history of failed or mixed delirium trials raises pivotal risk.
  • Equity market access: prior raisings at A$0.001 (pre-consolidation) demonstrate how severe dilution can become.
  • IPR&D impairment: A$6.75M intangible plus A$0.82M goodwill could be written down on adverse data (4E Note 6).
  • Formulation design-arounds: competitors may develop alternative injectable atypicals.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
17 Jun 2025Peter Christie appointed directorStart of board renewal
18 Jun 2025Placement: 308.4M shares at A$0.001 raising A$308kEmergency funding at near-zero price
30 Jun 2025FY2025 year-end: cash A$742k, equity A$733k; Nucleus IP fully impairedDistress low point
1 Jul 2025CEO role made redundantCost cutting; leadership vacuum
Jul 2025Board restructured to pursue deoxymab out-licensing and new opportunitiesStrategic reset
28 Aug 2025Entitlement offer shares issued (423.5M + 105.9M free attaching)Recapitalisation
4 Sep 2025Shortfall placement of 1.35B shares + 337.7M free attaching; Uvarov and Christie participateNew control group emerges
9 Oct 2025AGM elects Christie and UvarovGovernance
16 Oct 202515-for-1 consolidationCapital structure clean-up
22 Oct 2025Underwriter/lead-manager shares; Campbell paid 10.7M shares in lieu of cash entitlements; Uvarov tranche 2Cash preservation
10 Nov 2025Campbell resigns; Leedman appointed; office relocated; new company secretariesCompletion of board turnover
26 Nov 2025Reliis acquisition announcedPivot to reformulation/CNS
19 Jan 2026General meeting approves ReliisShareholder endorsement
28 Jan 2026Reliis completion; Kite and Cercarelli join boardClinical-stage pipeline
29 Jan 2026191.7M consideration/facilitation shares issued at A$0.03Dilution
30 Jan 2026Dec-25 quarter 4C: op outflow A$674k; cash A$1.9MLiquidity
10 Feb 2026Leedman incentive options; option exerciseIncentives
12 Feb 2026Dr Samantha South appointed CEO (effective 16 Feb)Execution leadership
26 Feb 2026H1 FY2026 loss A$3.02M; no R&D claims lodged during restructureEarnings
Mar-26 quarterBioCina engineering batch begins; US regulatory engagement starts; Yale US$100,500 licence fee paidOperational progress
16 Apr 2026Trading halt pending raise—
20 Apr 2026A$3.15M placement at A$0.024 with 1-for-4 options (A$0.048) via TemplarFunding Phase 1a
30 Apr 2026Mar-26 quarter 4C: cash A$1.196M; op outflow A$748kLiquidity
15 May 2026Updated Mar-26 quarter 4C lodgedDisclosure correction
20 May 2026CMAX (site) and Alithia (CRO) appointed; dosing targeted Q3Trial infrastructure
8 Jun 2026General meeting approves placement options and director participationGovernance
30 Jun 2026Sigma-Aldrich licence terminatedLegacy cost exit
3 Jul 20266.67M director placement shares (A$160k)Insider alignment
13 Jul 2026Binding Yale agreement on deoxymab IP (50% revenue share)Platform monetisation
15 Jul 202632.8M free attaching options and 9.2M broker options expireOverhang reduction
22 Jul 2026Jun-26 quarter 4C: cash A$3.36MLiquidity
27 Jul 2026TechKnow Invest Roadshow presentationInvestor marketing
28 Aug 2026HREC approval for Phase 1aRegulatory milestone
31 Aug 2026FY2026 Appendix 4E (unaudited): loss A$3.41M; going-concern material uncertainty expectedFinancial risk flagged
23 Sep 2026First participants dosed in Phase 1aClinical-stage transition
29 Sep 2026Cohort 1 (n=4) completes dosing and follow-upOn-schedule execution
Oct 2026 (targeted)Safety Review Committee to assess Cohort 1 before Cohort 2Near-term catalyst

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

1 chart
Results by Segment: Segment other income — Biopharma R&D fell from AUD 3.3 Mn in FY2022 to AUD 0 Mn in FY2026.
Patrys Limited — Results by Segment
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Segment other income — Biopharma R&D3.32.91.40.80
Segment pre-tax loss — Biopharma R&D-6.8-7.1-3.5-3-3.4

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.